Dopamine agonists and Parkinson's disease progression: What can we learn from neuroimaging studies
- 24 March 2003
- journal article
- review article
- Published by Wiley in Annals of Neurology
- Vol. 53 (S3) , S160-S169
- https://doi.org/10.1002/ana.10486
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT studyMovement Disorders, 2001
- Reproducibility and Effect of Levodopa on Dopamine Transporter Function Measurements: A [18F]CFT PET StudyJournal of Cerebral Blood Flow & Metabolism, 2000
- CEP‐1347 (KT7515), an Inhibitor of JNK Activation, Rescues Sympathetic Neurons and Neuronally Differentiated PC12 Cells from Death Evoked by three Distinct InsultsJournal of Neurochemistry, 1999
- Effect of treatment withL-dopa/carbidopa orL-selegiline on striatal dopamine transporter SPECT imaging with [123I]?-CITMovement Disorders, 1999
- Experimental Therapeutics of Neurodegenerative Disorders: Unmet NeedsScience, 1998
- Early Treatment of Parkinson??s Disease with Cabergoline Delays the Onset of Motor ComplicationsDrugs, 1998
- [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- Clinical observations on the rate of progression of idiopathic parkinsonismBrain, 1994
- Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1993